Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Feb;86(2):274-284.
doi: 10.1111/bcp.14174. Epub 2020 Jan 14.

Off-label use of tacrolimus in children with glomerular disease: Effectiveness, safety and pharmacokinetics

Guo-Xiang Hao  1 , Lin-Lin Song  2 , Dong-Feng Zhang  3 , Le-Qun Su  2 , Evelyne Jacqz-Aigrain  4 , Wei Zhao  1   2
Affiliations
Review

Off-label use of tacrolimus in children with glomerular disease: Effectiveness, safety and pharmacokinetics

Guo-Xiang Hao et al. Br J Clin Pharmacol. 2020 Feb.

Abstract

Glomerular diseases are leading causes of end-stage renal disease in children. Tacrolimus is frequently used off-label in the treatment of glomerular diseases. The effectiveness, safety and pharmacokinetic data of tacrolimus in the treatment of glomerular diseases in children are reviewed in this paper to provide evidence to support its rational use in clinical practice. The remission rates in previously published studies were different. In 19 clinical trials on children with nephrotic syndrome, the overall remission rate was 52.6-97.6%. In four clinical trials on children with lupus nephritis, the overall remission rate was 81.8-89.5%. In a pilot study with paediatric Henoch-Schönlein purpura nephritis patients, the overall remission rate was 100.0%. Infection, nephrotoxicity, gastrointestinal symptoms and hypertension are the most common adverse events. Body weight, age, CYP3A5 genotype, cystatin-C and daily dose of tacrolimus may have significant effects on the pharmacokinetics of tacrolimus in children with glomerular disease. More prospective controlled trials with long follow-up are needed to demonstrate definitely the effectiveness, safety and pharmacokinetics of tacrolimus in children with glomerular diseases.

Keywords: children; glomerular disease; tacrolimus.

PubMed Disclaimer

Conflict of interest statement

The authors have no competing interest to declare.

References

    1. Bieber T. Topical tacrolimus (FK 506): a new milestone in the management of atopic dermatitis. J Allergy Clin Immunol. 1998;102(4 Pt 1):555‐557. - PubMed
    1. Motamedi H, Cai SJ, Shafiee A, Elliston KO. Structural organization of a multifunctional polyketide synthase involved in the biosynthesis of the macrolide immunosuppressant FK506. Eur J Biochem. 1997;244(1):74‐80. - PubMed
    1. Hooks MA. Tacrolimus, a new immunosuppressant–a review of the literature. Ann Pharmacother. 1994;28(4):501‐511. - PubMed
    1. Li S, Yang H, Guo P, et al. Efficacy and safety of immunosuppressive medications for steroid‐resistant nephrotic syndrome in children: a systematic review and network meta‐analysis. Oncotarget. 2017;8(42):73050‐73062. - PMC - PubMed
    1. Tullus K, Webb H, Bagga A. Management of steroid‐resistant nephrotic syndrome in children and adolescents. Lancet Child Adolesc Health. 2018;2(12):880‐890. - PubMed

Publication types